Unknown

Dataset Information

0

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.


ABSTRACT: OBJECTIVE:To evaluate upadacitinib efficacy and safety dose response in Japanese patients with active RA and an inadequate response to conventional synthetic DMARDs (csDMARDs). METHODS:This was a multicentre, phase IIb/III, dose-ranging study conducted in Japan, in which patients on previously stable csDMARDs were randomized to receive upadacitinib 7.5, 15 or 30?mg once daily or matching placebo for a 12-week double-blind period. The primary endpoint was a 20% improvement in ACR criteria (ACR20) response at week 12 using non-responder imputation. Key secondary endpoints included ACR50, ACR70 and 28-joint DAS with CRP (DAS28-CRP) remission and low disease activity. Adverse events were also assessed. RESULTS:Of 197 patients treated, 187 completed the double-blind period. At week 12, more patients receiving upadacitinib 7.5, 15 or 30?mg vs placebo met the ACR20 response (75.5%, 83.7%, 80.0% vs 42.9%; P?

SUBMITTER: Kameda H 

PROVIDER: S-EPMC7590414 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.

Kameda Hideto H   Takeuchi Tsutomu T   Yamaoka Kunihiro K   Oribe Motohiro M   Kawano Mitsuhiro M   Zhou Yijie Y   Othman Ahmed A AA   Pangan Aileen L AL   Kitamura Susumu S   Meerwein Sebastian S   Tanaka Yoshiya Y  

Rheumatology (Oxford, England) 20201101 11


<h4>Objective</h4>To evaluate upadacitinib efficacy and safety dose response in Japanese patients with active RA and an inadequate response to conventional synthetic DMARDs (csDMARDs).<h4>Methods</h4>This was a multicentre, phase IIb/III, dose-ranging study conducted in Japan, in which patients on previously stable csDMARDs were randomized to receive upadacitinib 7.5, 15 or 30 mg once daily or matching placebo for a 12-week double-blind period. The primary endpoint was a 20% improvement in ACR c  ...[more]

Similar Datasets

| S-EPMC7789301 | biostudies-literature
| S-EPMC7892382 | biostudies-literature
| S-EPMC8645276 | biostudies-literature
| S-EPMC10423494 | biostudies-literature
| S-EPMC8516509 | biostudies-literature
| S-EPMC9886207 | biostudies-literature
| S-EPMC8184701 | biostudies-literature
| S-EPMC8053169 | biostudies-literature
| S-EPMC7892371 | biostudies-literature
| S-EPMC7158206 | biostudies-literature